CHUK and prostate cancer: Consistent with the identification of IKKα as a therapeutic target and its involvement in prostate cancer, we hypothesized that suppression of IKKα kinase activation affecting downstream NF-ĸB signaling by apigenin might markedly reduce cancer progression.